Researched by Belong.Life and published by ASCO
Data from the Belong PPN successfully captured the spectrum of PD-1 inhibitors’ reported AEs. Analyzing PRO of post approval treatments could provide deeper understanding of treatment patterns, expose limiting AE that bear implications on cost of treatment, indicate patients’ quality of life (QOL), improve management recommendations and provide a comprehensive outlook of patients’ outcomes.
Belong.Life is leading the charge in elevating patient engagement using conversational AI, big data and active patient communities. Belong’s key solutions include the world’s largest social and professional networks for people living with cancer (Belong – Beating Cancer Together) and multiple sclerosis (BelongMS), and the BelongAI health-grade patient engagement and support platforms (including Dave – Cancer Mentor, Tara for clinical trial matching and more) which utilize AI to proactively support and empower patients throughout their healthcare journey. By enhancing patient education and providing 24/7 support, as well as access to relevant clinical trials, Belong is contributing to improved healthcare outcomes globally.
